chemotherapy
Jump to navigation
Jump to search
Introduction
Treatment of disease with chemicals or pharmaceutical agents, generally used in reference to treatment of neoplastic disease.
Indications
- curable by chemotherapy
- chemotherapy is beneficial
- chemotherapy may have some benefit
- ADJUVANT chemotherapy is beneficial
- breast carcinoma
- colorectal carcinoma, stage III
- osteogenic sarcoma
- ovarian carcinoma, stage III
- testicular carcinoma
Contraindications
- cancer patients with poor performance status where palliative care may be better option[1]
* risk factors for chemotherapy toxicity[16]
- >= 1 fall in the past 6 months
- limited ability to walk 1 block
- social isolation due to physical disability or emotional disorder
- hearing loss
- needing assistance with medications
Adverse effects
- see specific agent
- generally toxicity to rapidly dividing cells:
- myelosuppression: most cytotoxic drugs
- major bleeding including intracranial hemorrhage associated with thrombocytopenia[18]
- bleeding risk after chemotherapy (10%)[18]
- bleeding risk greater for platelet counts < 5000/uL than > 80,000/uL, but no clear pattern of decreasing risk with increasing platelet counts[18]
- bleeding risk greater if hematocrit < 25 (RR=1.3), aPTT > 30 (RR=1.4) or > 50 (RR=2.3), INR > 1.2 (RR=1.5) or > 1.5 (RR=2.0)[18]
- RBC transfusion or platelet transfusion not associated with diminished next day bleeding[18]
- major bleeding including intracranial hemorrhage associated with thrombocytopenia[18]
- nausea/vomiting[13]:
- cisplatin doxorubicin, cyclophosphamide
- treat with ondansetron or palonosetron + high-dose glucocorticoid[1]
- gastrointestinal
- diarrhea: 5FU, capecetabine, ironotecan
- stomatitis, colitis: fluropyrimidines (5-fluorouracil)
- colitis, hepatitis: immunotherapy
- dermatology
- alopecia: doxorubicin, cyclophosphamide, paclitaxel
- scalp cooling cap may preserve hair in 50% of women
- hand-foot syndrome: fluropyrimidines (5-fluorouracil)
- pustular acneiform eruptions: EGFR inhibitors
- alopecia: doxorubicin, cyclophosphamide, paclitaxel
- mucositis, stomatitis: doxorubicin, methotrexate
- vesicant: doxorubicin, mitomycin
- peripheral neuropathy:[21]
- paclitaxel, docetaxel, cisplatin, vincristine
- duloxetine first line for painful peripheral neuropathy[7]
- pulmonary toxicity (pneumonitis): bleomycin, mitomycin, immunotherapy
- nephrotoxicity/urogenital:
- cisplatin, ifosfamide: renal tubular damage, CKD, cystitis
- cardiotoxicity:
- doxorubicin: dose-related heart failure (irreversible)
- trastuzumab: heart failure (not dose-related, reversible)
- checkpoint inhibitor: myocarditis, pericarditis
- endocrine:
- gonadal toxicity:
- musculoskeletal:
- carcinogenicity:
- extravasation injury: anthracyclines; vinca alkaloids
- nail changes[20]
- in older adults (compared with younger patients)[9]
- nausea/vomiting & alopecia less prominent
- diarrhea & neuropathy are more common
- mucositis, cardiotoxicity & central neurotoxicity are more common & more severe in the elderly
- myelotoxicity can be more severe & prolonged in the elderly
- infections related to myelosuppression may be more common in the elderly[9]
Mechanism of action
- interference with DNA synthesis
- purine/pyrimidine analogues
- methotrexate
- DNA-binding
- microtubule inhibition
- recruitment of cytotoxic immune-cells (investigational)
- bifunctional antibodies that link natural killer-cells with cancer cells[4]
* Generally, chemotherapy effective on replicating cells.
Mechanism of chemotherapy failure:
- tumor cell heterogeneity
- cells resistant to chemotherapeutic agents
- decreased drug uptake
- increased drug efflux
- decreased drug activation
- increased drug inactivation
- increased production of target enzyme
- large number of non-cycling or resting cells
- pharmacologic sanctuaries
- blood-tissue barriers
- blood supply-tumor barriers
- fatty acid 16:4(n-3) in fish oil associated with resistance to chemotherapy[11]
- no age-associated resistance to chemotherapy[9]
Complications
- increased risk for metabolic syndrome, especially with combination chemotherapy[1]
- increased risk of cardiovascular disease[1]
- cardiovascular risk factors increase cardiotoxicity of chemotherapy[1]
- anthracycline cardiotoxicity manifests as irreversible dilated cardiomyopathy
- trastuzumab cardiotoxicity presents as reversible LV systolic dysfunction
- chemotherapy-induced anemia
- treat with packed red cells even if normal iron studies & with nephrotoxic chemotherapeutic agents[24]
- cognitive impairment
- acknowlege & validate, offer behavioral therapy[1]
Comparative biology
- Mullerian inhibiting substance results in complete arrest of follicle development
- ovarian reserve remains stable, & contraception is induced for as long as high blood levels of Mullerian inhibiting substance persist
- treatment of female mice high levels of Mullerian inhibiting substance protected primordial ovarian follicle damage from carboplatin, doxorubicin, or cyclophosphamide
- cessation Mullerian inhibiting substance treatment resulted in normal activation of the ovarian follicles[17]
Notes
- patients's often expect cure from palliative chemotherapy[6]
- chemotherapy cost almost 60% more, or $90,144/year in hospital than in a community oncology practice, & patients were more likely to visit the emergency department treatment[19]
- avoid fish oil during chemotherapy[11]
- at home chemotherapy is popular among cancer patients[22]
More general terms
More specific terms
- adjuvant chemotherapy
- brain intracavitary chemotherapy
- chemoradiation (CRT)
- chemotherapy for breast cancer
- chemotherapy via bladdder irrigation
- conversion chemotherapy
- hyperthermic intraperitoneal chemotherapy
- neoadjuvant chemotherapy
- palliative chemotherapy
- regional chemotherapy
Additional terms
- adjuvant
- antineoplastic agent (chemotherapeutic agent)
- antineoplastic combination (combination chemotherapy)
- chemotherapy consolidation
- induction
- multidrug-resistance
- vaccination with intense chemotherapy
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Medical Knowledge Self Assessment Program (MKSAP) 17, 18, 19. American College of Physicians, Philadelphia 2015, 2018, 2022.
- ↑ Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 678-680
- ↑ Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 527
- ↑ 4.0 4.1 Bargou R et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008 Aug 15; 321:974. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18703743
- ↑ Scholl C et al Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009 May 29; 137:821 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19490892
Luo J et al A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009 May 29; 137:835. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19490893 - ↑ 6.0 6.1 Weeks JC et al. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med 2012 Oct 25; 367:1616 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23094723
Smith TJ and Longo DL. Talking with patients about dying. N Engl J Med 2012 Oct 25; 367:1651 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23094729 - ↑ 7.0 7.1 Smith EM et al Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy. A Randomized Clinical Trial. JAMA. 2013;309(13):1359-1367 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23549581 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=1674238
- ↑ 8.0 8.1 Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol. 2008 Sep;59(3):524-9 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18694683
- ↑ 9.0 9.1 9.2 9.3 Geriatric Review Syllabus, 8th edition (GRS8) Durso SC and Sullivan GN (eds) American Geriatrics Society, 2013
Geriatric Review Syllabus, 11th edition (GRS11) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2022 - ↑ Hurria A, Togawa K, Mohile SG et al Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011 Sep 1;29(25):3457-65 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21810685
- ↑ 11.0 11.1 11.2 11.3 Daenen LGM et al Increased Plasma Levels of Chemoresistance-Inducing Fatty Acid 16:4(n-3) After Consumption of Fish and Fish Oil. JAMA Oncol. Published online April 02, 2015. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26181186 <Internet> http://oncology.jamanetwork.com/article.aspx?articleid=2212208
- ↑ Yeh ET, Tong AT, Lenihan DJ et al Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004 Jun 29;109(25):3122-31. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15226229
- ↑ 13.0 13.1 Navari RM, Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 2016; 374:1356-1367. April 7, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27050207 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMra1515442
- ↑ Maggiore RJ, Dale W, Gross CP et al Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment. J Am Geriatr Soc. 2014 Aug;62(8):1505-12. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25041361 Free PMC Article
- ↑ Klepin HD, Pitcher BN, Ballman KV et al Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance). J Oncol Pract. 2014 Sep;10(5):e285-92. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25074878 Free PMC Article
- ↑ 16.0 16.1 Geriatric Review Syllabus, 9th edition (GRS9) Medinal-Walpole A, Pacala JT, Porter JF (eds) American Geriatrics Society, 2016
- ↑ 17.0 17.1 Kano M et al. AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy. Proc Natl Acad Sci U S A 2017 Feb 28; 114:E1688. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28137855 Free PMC Article <Internet> http://www.pnas.org/content/114/9/E1688
Woodruff TK. A win-win for women's reproductive health: A nonsteroidal contraceptive and fertoprotective neoadjuvant. Proc Natl Acad Sci U S A 2017 Feb 28; 114:2101. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28213496 <Internet> http://www.pnas.org/content/114/9/2101 - ↑ 18.0 18.1 18.2 18.3 18.4 18.5 Uhl L, Assmann SF, Hamza TH et al. Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial. Blood 2017 Sep 7; 130:1247 PMID: https://www.ncbi.nlm.nih.gov/pubmed/28679741
- ↑ 19.0 19.1 Nelson R Community Cancer Care 'Much Cheaper' Than Hospital Medscape - Oct 11, 2017. https://www.medscape.com/viewarticle/886890
The Value of Community Oncology. Site of Care Cost Analysis. Xcenda. Sept 25, 2017 https://www.communityoncology.org/wp-content/uploads/2017/09/Site-of-Care-Cost-Analysis-White-Paper_9.25.17.pdf - ↑ 20.0 20.1 Alzahrani MF, AlJasser MI Images in Clinical Medicine: Nail Changes during Chemotherapy. N Engl J Med 2018; 379:1561 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30332576 Free full text https://www.nejm.org/doi/full/10.1056/NEJMicm1801702
- ↑ 21.0 21.1 Sutton J, Leapman M Chemo-Induced Peripheral Neuropathy is Underreported - Managing this side effect will take better medications, non-drug strategies, and patient-physician communication. https://www.medpagetoday.com/resource-centers/spotlight-her2-positive-breast-cancer/chemo-induced-peripheral-neuropathy-underreported/2650
- ↑ 22.0 22.1 Mohile SG, Dale W, Somerfield MR et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018;36(22):2326-2347 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29782209 PMCID: PMC6063790 Free PMC article https://ascopubs.org/doi/10.1200/JCO.2018.78.8687
- ↑ At-Home Cancer Treatment Medscape - Video https://www.medscape.com/resource/oncology-cancer-treatment-at-home
- ↑ 24.0 24.1 NEJM Knowledge+
Gilreath JA, Rodgers GM. How I treat cancer-associated anemia. Blood. 2020 Aug 13;136(7):801-813. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32556170 Free article. Review.